CRISPR Therapeutics AG
NASDAQ:CRSP

Watchlist Manager
CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG
NASDAQ:CRSP
Watchlist
Price: 40.94 USD 1.14% Market Closed
Market Cap: 3.5B USD
Have any thoughts about
CRISPR Therapeutics AG?
Write Note

CRISPR Therapeutics AG
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CRISPR Therapeutics AG
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
CRISPR Therapeutics AG
NASDAQ:CRSP
Cash from Operating Activities
-$188.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Cash from Operating Activities
-$118.7m
CAGR 3-Years
11%
CAGR 5-Years
0%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Cash from Operating Activities
CHf43.7m
CAGR 3-Years
N/A
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Cash from Operating Activities
-CHf62m
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Cash from Operating Activities
CHf10.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Cash from Operating Activities
-CHf2.4m
CAGR 3-Years
20%
CAGR 5-Years
28%
CAGR 10-Years
N/A
No Stocks Found

CRISPR Therapeutics AG
Glance View

Market Cap
3.5B USD
Industry
Biotechnology

CRISPR Therapeutics AG is at the forefront of revolutionizing modern medicine through gene-editing technology. Founded on the groundbreaking research of CRISPR-Cas9, a tool that allows scientists to precisely alter an organism’s DNA, the company has swiftly emerged as a leader in the biotech arena. Situated in Switzerland, with significant operations in the United States, CRISPR Therapeutics aims to translate this cutting-edge science into transformative therapies. Its portfolio highlights collaborative efforts with other industry giants to develop treatments for serious genetic diseases, such as its flagship program targeting sickle cell disease and beta-thalassemia. By leveraging its proprietary CRISPR platform, the company focuses on developing gene-based medicines that address the root causes of illnesses, marking a departure from traditional symptom management to potentially groundbreaking cures. The business model of CRISPR Therapeutics is both innovative and strategic. Monetization is achieved through a blend of partnerships, licensing agreements, and direct therapeutic development. The company collaborates with various pharmaceutical entities, creating a network of shared knowledge and resources that accelerates the commercialization of therapies. These alliances facilitate shared risk and reward, allowing CRISPR Therapeutics to generate revenue while advancing its research and development pipeline. Moreover, the successful progression of any internally-developed therapies into approved treatments has the potential to unlock significant financial returns, both from sales and potential royalties. True to its visionary roots, CRISPR Therapeutics not only pursues immediate financial success but also seeks to redefine the landscape of genetic medicine with the long-term goal of delivering curative treatments for numerous genetic conditions.

CRSP Intrinsic Value
100.48 USD
Undervaluation 59%
Intrinsic Value
Price

See Also

What is CRISPR Therapeutics AG's Cash from Operating Activities?
Cash from Operating Activities
-188.8m USD

Based on the financial report for Sep 30, 2024, CRISPR Therapeutics AG's Cash from Operating Activities amounts to -188.8m USD.

What is CRISPR Therapeutics AG's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 1Y
32%

Over the last year, the Cash from Operating Activities growth was 32%.

Back to Top